An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen-activated T lymphocytes. 1995

T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
Department of Immunology, Faculty of Medicine, University of Tokyo, Japan.

Lymphocytes are particularly susceptible to DNA damage-induced apoptosis, a response which may serve as a form of 'altruistic suicide' to counter their intrinsic high potential for mutation and clonal expansion. The tumour suppressor p53 has been shown to regulate this type of apoptosis in thymocytes, but an as yet unknown, p53-independent pathway(s) appears to mediate the same event in mitogen-activated mature T lymphocytes. Here we show DNA damage-induced apoptosis in these T lymphocytes is dependent on the antioncogenic transcription factor interferon regulatory factor (IRF)-1. Thus two different anti-onco-genic transcription factors, p53 and IRF-1, are required for distinct apoptotic pathways in T lymphocytes. We also show that mitogen induction of the interleukin-1 beta converting enzyme (ICE) gene, a mammalian homologue of the Caenorhabditis elegans cell death gene ced-3, is IRF-1-dependent. Ectopic overexpression of IRF-1 results in the activation of the endogenous gene for ICE and enhances the sensitivity of cells to radiation-induced apoptosis.

UI MeSH Term Description Entries
D008213 Lymphocyte Activation Morphologic alteration of small B LYMPHOCYTES or T LYMPHOCYTES in culture into large blast-like cells able to synthesize DNA and RNA and to divide mitotically. It is induced by INTERLEUKINS; MITOGENS such as PHYTOHEMAGGLUTININS, and by specific ANTIGENS. It may also occur in vivo as in GRAFT REJECTION. Blast Transformation,Blastogenesis,Lymphoblast Transformation,Lymphocyte Stimulation,Lymphocyte Transformation,Transformation, Blast,Transformation, Lymphoblast,Transformation, Lymphocyte,Activation, Lymphocyte,Stimulation, Lymphocyte
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010750 Phosphoproteins Phosphoprotein
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D003208 Concanavalin A A MANNOSE/GLUCOSE binding lectin isolated from the jack bean (Canavalia ensiformis). It is a potent mitogen used to stimulate cell proliferation in lymphocytes, primarily T-lymphocyte, cultures.
D003546 Cysteine Endopeptidases ENDOPEPTIDASES which have a cysteine involved in the catalytic process. This group of enzymes is inactivated by CYSTEINE PROTEINASE INHIBITORS such as CYSTATINS and SULFHYDRYL REAGENTS.
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA
D004249 DNA Damage Injuries to DNA that introduce deviations from its normal, intact structure and which may, if left unrepaired, result in a MUTATION or a block of DNA REPLICATION. These deviations may be caused by physical or chemical agents and occur by natural or unnatural, introduced circumstances. They include the introduction of illegitimate bases during replication or by deamination or other modification of bases; the loss of a base from the DNA backbone leaving an abasic site; single-strand breaks; double strand breaks; and intrastrand (PYRIMIDINE DIMERS) or interstrand crosslinking. Damage can often be repaired (DNA REPAIR). If the damage is extensive, it can induce APOPTOSIS. DNA Injury,DNA Lesion,DNA Lesions,Genotoxic Stress,Stress, Genotoxic,Injury, DNA,DNA Injuries
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins

Related Publications

T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
May 2018, Environmental and molecular mutagenesis,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
August 2002, Cancer,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
April 2010, Cell death and differentiation,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
October 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
June 2000, European journal of pharmacology,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
June 1988, Biochemical and biophysical research communications,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
November 2006, Cancer research,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
August 2017, Biochemical pharmacology,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
May 1999, Immunology,
T Tamura, and M Ishihara, and M S Lamphier, and N Tanaka, and I Oishi, and S Aizawa, and T Matsuyama, and T W Mak, and S Taki, and T Taniguchi
January 2000, Hypertension (Dallas, Tex. : 1979),
Copied contents to your clipboard!